门冬胰岛素30致局限性脂肪萎缩

Localized lipoatrophy induced by insulin aspart 30

1例52岁女性2型糖尿病患者,先后用门冬胰岛素和精蛋白锌胰岛素治疗。3个月后,改为门冬胰岛素30皮下注射(剂量不详)。约1个月后,患者的注射部位出现皮疹伴瘙痒,持续2～3h后消退。约2个月后,患者的前臂和腹部注射部位出现局限性脂肪萎缩区,直径1～4cm。停用门冬胰岛素30,改为口服那格列奈60mg,2次/d。1年后,患者的脂肪萎缩区基本消失。

A 52-year-old woman with type Ⅱ diabetes mellitus initially treated with insulin aspart and subsequently insulin zinc protamine. About 3 months later, the regimen was changed to subcutaneous injection of insulin aspart 30 （dosage not stated）. About one month later, skin rash and pruritus occurred at the injection sites. The skin disorders lasted from 2 to 3 hours, and then resolved. About further 2 months later, she presented with localized lipoatrophic areas （ about 1 ～4 cm in diameter） at insulin aspart 30 injection sites on her forearm and abdomen. Insulin aspart 30 was discontinued, and switched to oral nateglinide 60 mg twice daily. One year later, her areas of lipoatrophy basically disappeared.